Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Moreau, Philippe; Avet‐Loiseau, Hervé; Façon, Thierry; Attal, Michel; Tiab, Mourad; Hulin, Cyrille; Doyen, Chantal; Garderet, Laurent; Randriamalala, Edouard; Araujo, Carla; Lepeu, G.; Marit, Gérald; Caillot, Denis; Escoffre, Martine; Lioure, Bruno; Benboubker, Lotfi; Pegourié, Brigitte; Kolb, Brigitte; Marie Stoppa, Anne; Fuzibet, Jean‐Gabriel; Decaux, Olivier; Dib, Mamoun; Berthou, Christian; Chaleteix, Carine; Sebban, Catherine; Traullé, Catherine; Fontan, Jean; Wetterwald, Marc; Lenain, Pascal; Mathiot, Claire; Harousseau, Jean‐Luc

doi:10.1182/blood-2011-05-355081

Public

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Published in Blood • Aug 18, 2011

Authors:

Philippe Moreau

Hervé Avet‐Loiseau

Thierry Façon

Abstract

The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-dexamethasone (VD) as induction before high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) to a combination consisting of reduced doses of bortezomib and thalidomide plus dexamethasone (vtD)...

Subject

Bortezomib

Dexamethasone

Multiple myeloma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!